In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.
Latest Ratings for ACAD
DateFirmActionFromTo Mar 2022Cantor FitzgeraldMaintainsOverweight Mar 2022Goldman SachsMaintainsNeutral Mar 2022MizuhoMaintainsNeutral